Phase 3 Trial of P2B001 for Early-Stage Parkinson's Disease Begins With First Patients Receiving First Dose

Wednesday, February 07, 2018


The drug P2B001(Pharma Two B) is a combination product of pramipexole 0.6mg and rasagiline 0.75 mg given together once daily. Rasagiline is a monoamine oxidase inhibitor used to treat Parkinson’s disease (PD) alone or, more commonly, as an adjunct to treatment with levodopa. Pramipexole is a dopamine agonist often used in early-stage PD treatment with the goal of postponing initiation of levodopa treatment due to the significant complications of prolonged use of levodopa.

Based on positive results from a phase 2b pivotal study that suggested efficacy and minimal side effects for P2B001 in early-stage PD, Pharma Two B designed and initiated a multinational phase 3 trial and today announced that the first patients in that trial had received their first doses of P2B001.

The study is a twelve-week long, randomized, double-blind, double dummy, 4-arm, parallel study that explores the efficacy, tolerability, and safety of P2B001for patients with early-stage PD compared to rasagiline alone, pramipexole along, and pramipexole ER titrated to an optimal dose. Investigators from 70 international sites will enroll 525 untreated patients with early-stage PD and randomize them into one of the four treatment arms in the study.

Dr. Nurit Livnah, CEO of Pharma Two B said, "Pharma Two B is focused on successfully completing our phase 3 as planned and preparing for product launch in 2020. P2B001, once approved, is expected to provide early-stage Parkinson's patients with effective treatment with an improved safety profile. We believe P2B001 has the potential to become a leading therapy for early stage PD."

Ehud Marom, Chairman of Pharma Two B said: "Following a successful round of financing totaling $US 35 million which includes an investment by a Chinese pharmaceutical company who purchased the rights for the product in China. This fundraising enables Pharma Two B to complete the Phase 3 and expand its pipeline. We are currently focused on finding the best marketing partner to commercialize P2B001 and expand our portfolio."

Next Story

Comments

You must be logged in to leave a comment.